Part two of the program highlights China's impact on biotech, addressing innovative approaches to biologics beyond "Me Too" products. Topics include cost-effective drug development, scientific engineering, and accelerated clinical trials from diverse perspectives including CMCs, CEOs, CMOs, and Tech Ops.
Insights from PD-1/VEGF bispecifics and international data inform discussions on optimizing multi-specific oncology applications in immunotherapy. The program concludes with a partnership session focusing on mapping novel biological pathways and asset acquisition strategies.